Activity of Meropenem-Vaborbactam against Bacterial Isolates Causing Pneumonia in Patients in U.S. Hospitals during 2014 to 2018

Meropenem-vaborbactam is approved to treat hospital-acquired pneumonia (HAP), including ventilator-associated pneumonia (VAP), in Europe. Meropenem-vaborbactam activity was evaluated against 3,193 Pseudomonas aeruginosa and 4,790 Enterobacterales isolates causing pneumonia, including VAP, in hospita...

Descripción completa

Detalles Bibliográficos
Autores principales: Carvalhaes, Cecilia G., Shortridge, Dee, Sader, Helio S., Castanheira, Mariana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2020
Materias:
Epidemiology and Surveillance
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7038313/
https://www.ncbi.nlm.nih.gov/pubmed/31907187
http://dx.doi.org/10.1128/AAC.02177-19
_version_ 1783500611345448960
author Carvalhaes, Cecilia G.
Shortridge, Dee
Sader, Helio S.
Castanheira, Mariana
author_facet Carvalhaes, Cecilia G.
Shortridge, Dee
Sader, Helio S.
Castanheira, Mariana
author_sort Carvalhaes, Cecilia G.
collection PubMed
description Meropenem-vaborbactam is approved to treat hospital-acquired pneumonia (HAP), including ventilator-associated pneumonia (VAP), in Europe. Meropenem-vaborbactam activity was evaluated against 3,193 Pseudomonas aeruginosa and 4,790 Enterobacterales isolates causing pneumonia, including VAP, in hospitalized patients in the United States. Susceptibility testing was performed by using the broth microdilution method, and all carbapenem-resistant isolates were submitted for whole-genome sequencing. Meropenem-vaborbactam exhibited almost complete activity against Enterobacterales (>99.9% susceptible), including carbapenem-resistant Enterobacterales (CRE), and was also very active against P. aeruginosa isolates (89.5% susceptible).
format Online
Article
Text
id pubmed-7038313
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher American Society for Microbiology
record_format MEDLINE/PubMed
spelling pubmed-70383132020-03-06 Activity of Meropenem-Vaborbactam against Bacterial Isolates Causing Pneumonia in Patients in U.S. Hospitals during 2014 to 2018 Carvalhaes, Cecilia G. Shortridge, Dee Sader, Helio S. Castanheira, Mariana Antimicrob Agents Chemother Epidemiology and Surveillance Meropenem-vaborbactam is approved to treat hospital-acquired pneumonia (HAP), including ventilator-associated pneumonia (VAP), in Europe. Meropenem-vaborbactam activity was evaluated against 3,193 Pseudomonas aeruginosa and 4,790 Enterobacterales isolates causing pneumonia, including VAP, in hospitalized patients in the United States. Susceptibility testing was performed by using the broth microdilution method, and all carbapenem-resistant isolates were submitted for whole-genome sequencing. Meropenem-vaborbactam exhibited almost complete activity against Enterobacterales (>99.9% susceptible), including carbapenem-resistant Enterobacterales (CRE), and was also very active against P. aeruginosa isolates (89.5% susceptible). American Society for Microbiology 2020-02-21 /pmc/articles/PMC7038313/ /pubmed/31907187 http://dx.doi.org/10.1128/AAC.02177-19 Text en Copyright © 2020 Carvalhaes et al. https://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Epidemiology and Surveillance
Carvalhaes, Cecilia G.
Shortridge, Dee
Sader, Helio S.
Castanheira, Mariana
Activity of Meropenem-Vaborbactam against Bacterial Isolates Causing Pneumonia in Patients in U.S. Hospitals during 2014 to 2018
title Activity of Meropenem-Vaborbactam against Bacterial Isolates Causing Pneumonia in Patients in U.S. Hospitals during 2014 to 2018
title_full Activity of Meropenem-Vaborbactam against Bacterial Isolates Causing Pneumonia in Patients in U.S. Hospitals during 2014 to 2018
title_fullStr Activity of Meropenem-Vaborbactam against Bacterial Isolates Causing Pneumonia in Patients in U.S. Hospitals during 2014 to 2018
title_full_unstemmed Activity of Meropenem-Vaborbactam against Bacterial Isolates Causing Pneumonia in Patients in U.S. Hospitals during 2014 to 2018
title_short Activity of Meropenem-Vaborbactam against Bacterial Isolates Causing Pneumonia in Patients in U.S. Hospitals during 2014 to 2018
title_sort activity of meropenem-vaborbactam against bacterial isolates causing pneumonia in patients in u.s. hospitals during 2014 to 2018
topic Epidemiology and Surveillance
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7038313/
https://www.ncbi.nlm.nih.gov/pubmed/31907187
http://dx.doi.org/10.1128/AAC.02177-19
work_keys_str_mv AT carvalhaesceciliag activityofmeropenemvaborbactamagainstbacterialisolatescausingpneumoniainpatientsinushospitalsduring2014to2018
AT shortridgedee activityofmeropenemvaborbactamagainstbacterialisolatescausingpneumoniainpatientsinushospitalsduring2014to2018
AT saderhelios activityofmeropenemvaborbactamagainstbacterialisolatescausingpneumoniainpatientsinushospitalsduring2014to2018
AT castanheiramariana activityofmeropenemvaborbactamagainstbacterialisolatescausingpneumoniainpatientsinushospitalsduring2014to2018

Ejemplares similares